PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%
New York, December 20, 2023 – PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights Panbela Therapeutics, Inc. which has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. In July 2023, Panbela divested […]